News

News

Epitopea raises seed financing – $ 14M

IRICoR is delighted with the announcement made today by Epitopea, a transatlantic cancer immunotherapeutics company, on a $13.6M seed investment from a transatlantic syndicate of top-tier life sciences investors, including AdventLifeSciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.
The company’s proprietary technology provides an innovative approach to identifying shared, aberrantly expressed tumour specific antigens, known as […]

A new agreement for an international public-private research collaboration in drug discovery

IRICoR is delighted with the announcement made today by ONO Pharmaceutical Co., Ltd. (“ONO”), one of Japan’s largest clinical-stage pharmaceutical companies, on signing a collaboration agreement with Domain Therapeutics S.A. (“Domain”) and University of Montreal (“UdeM”), to discover new small molecules targeting G protein-coupled receptors (GPCRs) in the treatment of a metabolic disease.
“Very early on, we identified and supported this […]

Webinar IP

 
Aimed at research and life sciences professionals, IRICoR is very excited to invite you to its next workshop on intellectual property.
 
To mark World Intellectual Property Day, please join us on April 26, from 12:00 pm to 1:30 pm, during lunch break for this webinar on intellectual property, entitled: Patents: practical and strategic considerations
 
Our guest speaker, Mr. Alain Dumont, […]

IVADO interviewe Nadine Beauger

It is with pleasure that Mrs. Nadine Beauger, President and CEO of IRICoR, went “Under the microscope” of IVADO. “Under the microscope” is a project aimed at highlighting members of its community through short portraits.
Extract from the interview: “Our flexible project development model allows us to identify complementary expertise to include artificial intelligence know-how in drug discovery projects.”
Read the interview […]

The Making of Epitopea, a New Transatlantic Cancer Immunotherapeutics Venture

Sessions have been announced for the 7th annual Access to Innovation Conference. The virtual conference brings together all stakeholders in the life sciences sector, academia, research, health institutions, and government to share their insights into this year’s theme: Building on Excellence: A Vibrant Future for BC Life Sciences.
We are pleased to announce that IRICoR is a partner […]

Premières en affaires magazine

 
The new issue of Premières en affaires magazine is now available. IRICoR is proud to have collaborated on this edition.
 
Nadine Beauger, President and CEO of IRICoR and Anne Marinier, Director of Medicinal Chemistry and Director of the Drug Discovery Unit at IRIC, highlight the strength of a collaborative women and the importance of combining science and business, for the ultimate […]

Nadine Beauger, panellist at the Strategic Forum an initiative of the CCMM

On Monday, December 13, Nadine Beauger, IRICoR’s President and CEO, took part in the panel discussion: Leveraging our niches of excellence, along with Stéphane Létourneau, Executive Vice President at Mila, and Stéphane Paquet, President and CEO at Montréal International. This panel was presented as part of the Strategic Forum: The pharmaceutical industry: At the forefront of life sciences, an initiative […]

MEDIGENE, IRICoR, AND UdeM EXPAND ANALYSES OF POTENTIALLY NOVEL CANCER ANTIGENS

Martinsried, Germany and Montréal, Canada – Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, IRICoR, and the University of Montréal (Université de Montréal, UdeM) expand their mutual analyses of potentially novel cancer antigens.
In January 2020, Medigene entered into a research collaboration on novel cancer antigens for highly specific immunotherapies […]

Nadine Beauger, Panelist at the CSPC Conference

On November 22nd, Nadine Beauger, President and Chief Executive Officer of IRICoR, was invited as a panellist at the 13th Canadian Science Policy Conference, presented by the Canadian Science Policy Centre (CSPC). For this occasion, Nadine participated in the session “Realizing Canada’s Life Sciences Opportunities,” moderated by Gordon C. McCauley, President & CEO of adMare BioInnovations, along with Cate Murray, […]

LeadAction Ovarian Cancer Competition – a look back at research projects

In 2020, IRICoR concluded a major partnership with Ovarian Cancer Canada. By launching the pan-Canadian LeadAction Ovarian Cancer Competition, the 5th call for projects at IRICoR, these organizations aimed to fund innovative ovarian cancer research projects to accelerate the discovery of new treatments.
A few months ago, the winners of the Competition were announced. A total amount of $2.3M over two (2) years […]

« Previous Page | Next Page »

© 2008-2022 IRICoR